Clinical correlation studies have clearly demonstrated that obesity is associated with breast cancer risk and patient survival. Although several potential mechanisms linking obesity and cancers have been proposed, the detailed molecular mechanism of obesity-mediated breast tumorigenesis has not yet been critically evaluated. In the present study, we evaluated the effects of obesity on mammary tumor initiation and progression using mice with genetic and diet-induced obesity bearing mammary tumor xenografts and mouse mammary tumor virus-neu transgenic mice that were fed a high-fat diet. We demonstrate that obesity promoted mammary tumor growth and development in these animal models. Moreover, the expressions of tumor necrosis factor alpha (TNFα), vascular endothelial growth factor (VEGF), inhibitor of nuclear factor kappa-B beta (IKKβ), and mammalian target of rapamycin (mTOR) are upregulated in mammary tumors of obese mice, suggesting that the IKKβ/mTOR/VEGF signaling pathway is activated by TNFα in the tumors of obese mice. More importantly, inhibitors (rapamycin, bevacizumab, and aspirin) that target members of the pathway suppressed tumorigenesis and prolonged survival more effectively in obese mice than in non-obese mice. Here, we not only identified a specific signaling pathway that contributes to mammary tumorigenesis in obese mice but also a strategy for treating obesity-mediated breast cancer.
Introduction
Obesity is a serious health problem in the United States and is associated with increased risk of diabetes, hypertension, and cardiovascular diseases. Moreover, growing evidence has shown that obesity is a risk factor for multiple types of human cancer (1) (2) (3) (4) and known to be correlated with breast cancer tumorgenesis and development (5, 6) . Breast cancer is the second-leading cause of cancer-related deaths in women in the United States, and obese breast cancer patients have a higher risk of recurrent disease, higher metastasis and mortality rates, larger tumor masses, and a poorer prognosis than non-obese breast cancer patients (7) (8) (9) (10) (11) (12) .
Several mechanisms relating to breast cancer prognosis in obese patients have been proposed. For example, estrogen (13, 14) , which is expressed at significantly higher levels in obese postmenopausal women than in non-obese postmenopausal women, is believed to increase the risks of developing breast cancer (6) . The expression of insulin and insulin-like growth factors, which is also higher in obese patients, has also been proposed to play a role in breast cancer cell growth and survival (15) . In addition, adipose tissues that secrete adipokines, such as leptin, adiponectin, growth factors, and proinflammatory cytokines, also enhance cancer cell growth (16) (17) (18) . Particularly, recent studies have indicated that that expression of the inflammatory cytokine tumor necrosis factor alpha (TNFα) is increased in obese patients, thereby suggesting that this cytokine plays a role in obesity-mediated breast cancer development and progression (19, 20) . However, the specific signaling pathway linking TNFα and obesity to breast tumorigenesis and the exact mechanisms underlying the connection between obesity and breast cancer are still a matter of debate. Thus, investigating signaling pathways involved in obesity-mediated breast cancer, which could lead to the development of targeted therapies that inhibit obesity-related tumor growth, is a significant and timely goal.
Previously, we showed that TNFα induces the IKKβ/mTOR/VEGF pathway to promote breast cancer progression by inducing angiogenesis (21). The activated TNFα receptor activates IKKβ, which in turn phosphorylates tuberous sclerosis protein 1 (TSC1) and actives the downstream signaling pathway such as mTOR. Moreover, IKKβ activation, TSC1 phosphorylation, and VEGF expression are correlated with poor clinical outcome in breast cancer patients (21). Because obese patients have higher levels of adipocytes and thus can secrete more TNFα (22), we speculated that this newly identified mechanism could link TNFα-activated IKKβ/mTOR/VEGF (23) to obesity and therefore contribute to obesity-mediated breast cancer progression.
In this study, we sought to determine the effects of obesity on mammary tumor progression using two different mouse models of obesity: mice with genetic and diet-induced obesity (DIO) bearing orthotopic xenograft mammary tumors. Moreover, we also assessed the effects of diet-induced obesity on tumor initiation in a mouse mammary tumor virus (MMTV)-neu model. Table 1) starting at 4 weeks of age. DIO was initiated in mice via ad libitum access to high-fat food for at least 8-12 weeks as described previously (25) until the experiments were completed. ND and HFD mice were injected with mammary cancer cells were injected with 2 × 10 5 EO771 mammary adenocarcinoma cells at age 14 weeks. The OB mice, which spontaneously develop obesity even on ND (26, 27) , were fed only the ND and injected with 2 × 10 5 EO771 mammary adenocarcinoma cells at age 14 weeks. Mice were removed from the experiment when tumor size reaches over 1.5 cm diameters in accordance with the Institution Animal Care and Use Community (IACUC) guidelines. The incidence of spontaneous tumor growth in MMTV-neu mice was noted when tumors growth is larger than 5 mm in diameter in the mammary gland.
MMTV-neu develops mammary tumors spontaneously at about age 6-12 months (28, 29) . 
Statistical analysis
Data are shown as the mean ± standard deviation (SD) of 10 individual mice or treatments.
Statistical significance between groups was analyzed using a Student t-test or one-or two-way analysis of variance. Survival was analyzed using a Kaplan-Meier plot, and MMTV-neu mice 
Results

Genetic obesity and DIO promote mammary tumorigenesis and increase mortality
Although clinical evidence indicates that obesity is one of the major risk factors for breast cancer (35) , and despite the fact that researchers have proposed several mechanisms by which obesity and tumor progression are linked, limited information is available about the causal relationships between the molecular mechanisms and obesity-mediated breast cancer. To further explore the underlying mechanisms of obesity-mediated breast cancer, we first used two kinds of obesity mouse models, DIO and genetic obesity, to establish mammary tumor xenograft in these mice and further investigated the effects of obesity tumor progression.
We monitored the body weight of mice in these two models first and confirmed that these mice weighed more than control mice (Fig. 1A and 1B , upper panels). We then established mammary tumors in these mice and observed significantly higher tumor growth in obese mice (HFD/DIO and OB) than in lean mice (ND and WT) in both models (Fig. 1A and 1B, middle panels). Moreover, the survival rates of obese mice in both models were significantly lower than those of the control mice ( Fig. 1A and 1B Fig. 1A and 1B) . Together, these results indicate that obesity promoted mammary tumor growth in vivo and reduced median survival and that these animal models are feasible for studying the underlying mechanisms of obesity-mediated tumor progression.
In a previous study, we demonstrated that the IKKβ/mTOR/VEGF pathway was more highly activated by TNFα in the livers of obese mice that had been fed an HFD than in the livers of normal-weight mice that had been fed an ND (23). Moreover, TNFα expression was recently shown to induce liver inflammation and promote tumorigenesis in mice with DIO and genetic obesity (36) . TNFα, the first adipocytokine identified in adipose tissue, is known to contribute to inflammation-mediated tumor progression (21, 37, 38). To determine if the IKKβ/mTOR/VEGF signaling pathway is also involved in obesity-mediated mammary tumorigenesis, we harvested mammary tumors from these mice and subjected them to immunofluorescence staining.
Immunofluorescence staining ( Fig. 2A and 2B ) showed that TNFα and VEGF protein levels in tumors were significantly higher in mice with DIO and genetic obesity than in control (lean) mice. We also determined via enzyme-linked immunosorbent assay (ELISA) that circulating that obesity plays a role in promoting mammary tumorigenesis, at least in part, by enhancing tumor angiogenesis, which is in line with our previous studies that showed TNFα produced by adipose tissues increases of tumor angiogenesis (21, 36).
Blocking the IKKβ/mTOR/VEGF pathway inhibits obesity-mediated tumorigenesis
The data shown here suggest that the IKKβ/mTOR/VEGF pathway may play an important role in mammary tumor progression in obese mice. Thus, targeting this pathway may lead to new intervention strategies for obesity-mediated breast cancer. To determine whether inhibition of the IKKβ/mTOR/VEGF signaling pathway reduces the development of mammary tumor in DIO mice, we first established mammary tumors in obese and control mice as described above and then administered inhibitors or antagonists of this specific pathway to obese and control (lean) mice after the tumor volume reached a 3-5 mm in diameter. Interestingly, after treatment with aspirin (an IKKβ inhibitor), rapamycin (an mTOR inhibitor), or bevacizumab (a VEGF antagonist) for 2 weeks, a significant reduction in mammary tumor volume was observed in obese mice but not in control (lean) mice (left panels, Fig. 4A-C) .
To validate that these drugs indeed blocked the specific pathway we proposed, tumor samples from the mice treated or untreated with the drugs were subjected to immunostaining with specific antibodies against the IKKβ/mTOR/VEGF pathway. The activity of IKKβ, mTOR, and VEGFR, as indicated by their phosphorylation status, was reduced in tumor-bearing obese mice that were treated with aspirin, rapamycin, and bevacizumab, respectively (Fig. 4, middle and right panels). These results support our hypothesis that blocking the IKKβ/mTOR/VEGF pathway could inhibit obesity-mediated breast tumorigenesis.
TNFα-mediated signaling pathway promotes the development of mammary tumors in mice
The data above strongly support the notion that the TNFα-induced signaling pathway plays a critical role in mammary tumor cell proliferation in obese mice. Next, we sought to determine whether the TNFα-mediated signaling pathway also promotes mammary tumor initiation in obese mice. To address this question, we used MMTV-neu transgenic mice, which develop mammary tumors spontaneously at about age 6-12 months (28, 29) . After the weaning stage, one group of MMTV-neu transgenic mice was fed an HFD, and the other group was fed an ND. We monitored tumor development and found that spontaneous development of mammary tumors was accelerated in the MMTV-neu transgenic mice group fed the HFD compared with the group that was fed an ND (Fig. 5A) , suggesting that obesity also promotes tumor initiation. Mice 
higher in mammary tumors of the HFD group than in the tumors of the ND group, thereby suggesting that the IKKβ/mTOR/VEGF pathway is also activated in the spontaneously developing mammary tumors of MMTV-neu transgenic mice with HFDs (Fig. 5B) .
Inhibition of the TNFα-mediated signaling pathway prevents the development of mammary tumor in mice
In a parallel experiment, after the weaning stage, the MMTV-neu transgenic mice were fed an HFD but treated with aspirin, rapamycin, or bevacizumab. We found that these IKKβ/mTOR/VEGF pathway inhibitors delayed mammary tumors development in MMTV-neu transgenic mice that were fed an HFD. The mice in the HFD, HFD aspirin-treated, HFD rapamycin-treated, and HFD bevacizumab-treated groups developed tumors from days 146 to 207, days 185 to 199, days 185 to 227, and days 185 to 243, respectively. The median time for tumor formation in both rapamycin-and bevacizumab-treated obese mice was 199 days, and the median time for tumor formation in the HFD group without drug treatment was 159 days (Fig.   6A ). In addition, immunofluorescence staining of tumor tissues also showed that phosphorylation of the IKKβ/mTOR/VEGF signaling pathway was decreased in mammary tumors of the obese MMTV-neu mice that were treated with these drugs (Fig. 6B) . Taken together, these results suggest that obesity promotes breast tumor initiation, at least in part, by 
the activation of the IKKβ/mTOR/VEGF pathway.
Discussion
In the present study, we demonstrated a novel molecular mechanism that provides a link between obesity and breast cancer in mouse models. We found that the expression of TNFα and IKKβ/mTOR/VEGF pathway (Supplementary Figure 3) . Interestingly, we found that when obese mice with mammary tumors were treated with these drugs, all of the specific target molecules in the IKKβ/mTOR/VEGF signaling pathway were inhibited. This is somewhat expected as aspirin, a phytochemical derivative with typically broad activity, has recently been shown to also activate AMPK, which influences the mTOR activity (44, 45) . Moreover, other studies have also reported the activation of IKKβ by VEGF via the Flk-1/Cbl/Akt signaling pathway. Therefore, IKKβ can be downregulated once VEGF is blocked by bevacizumab (46) . While pathways other than the one we proposed may play a role, our results provide a rationale for targeting the IKKβ/mTOR/VEGF pathway in obesity-mediated mammary tumor development.
Since aspirin did not significantly inhibit obesity-mediated mammary tumor incidence compared with rapamycin and bevacizumab in the MMTV-neu mouse model (Fig. 6A) , we further examined the effect of these drugs on inflammatory infiltration (CD45, leukocytes common antigen) induced by TNFα pro-inflammatory cytokine that is linked to tumor insurgence and tumor progression. We found inflammatory infiltration was more obvious in mice fed an HFD than those fed an ND and can be decreased by aspirin, rapamycin, or bevacizumab treatment ( Supplementary Fig. 4A ), suggesting that inflammation is one key point linking these factors. It is possible that the Her2/neu-mediated signaling pathway can overcome the inhibition of the IKKβ/mTOR/VEGF signaling pathway in the MMTV-neu model (47) Recent preclinical and clinical reports have shown that aspirin can be used for both cancer therapy and cancer prevention (48, 49) . Furthermore, epidemiologic evidence shows that aspirin can be used for adjuvant therapy in cancer patients (50) . However, in our MMTV-neu obesity mouse model, aspirin did not show inhibitory effects of mammary tumor initiation compared to rapamycin and bevacizumab (Fig. 6A) . Thus, in this particular mouse model (Her2-positive breast cancer), aspirin may not be a good cancer prevention drug but may be useful for cancer prevention for other types of breast cancers (ER-positive or triple-negative breast cancers). While clinical trials show that aspirin can reduce tumor incidence by 10% in all cancer types, we believe the benefit-to-risk ratio must be defined in different cancer types (51, 52) as side effects, including as gastrointestinal bleeding, from long-term aspirin treatment have been reported (48, 53, 54) .
Regarding the effect of angiogenesis on obesity, we did not find significant body weight loss in the aspirin/rapamycin/bevacizumab treatment group compared with the obese control group.
However, anti-angiogenesis approaches have been proposed as a method of limiting obesity, and treatment of obese mice with anti-angiogenesis inhibitors has been shown to reduce obesity.
Although the pathophysiological connection between angiogenesis and adipogenesis is well 
serve as a therapeutic target for other obesity-related human cancers.
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